Lactate dehydrogenase: a marker of diminished antitumor immunity.

Oncoimmunology
Sandra Van WilpeNiven Mehra

Abstract

Lactate dehydrogenase (LDH) levels are inversely related with response to checkpoint inhibitors. Elevated LDH levels are the product of enhanced glycolytic activity of the tumor and tumor necrosis due to hypoxia, the latter being associated with high tumor burden. In this review, we elucidate the effects of glycolysis and hypoxia on antitumor immunity and set forth ways to improve response to immunotherapy in cancer patients with elevated LDH levels. We discuss the current knowledge on combining immunotherapy with glycolysis inhibitors, anti-acidifying drugs, anti-angiogenic or cytoreductive therapy.

References

Jan 1, 1973·Journal of Surgical Oncology·D C WoodF Weber
Jan 1, 1997·Acta Oncologica·C G MilrossL Milas
Sep 23, 2000·Nature·P Carmeliet, R K Jain
Aug 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael I KoukourakisUNKNOWN Tumour Angiogenesis Research Group
Jan 27, 2007·Blood·Karin FischerMarina Kreutz
May 8, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sanjiv S AgarwalaAlexander M M Eggermont
Sep 30, 2010·The Journal of Experimental Medicine·Cesar A CorzoDmitry I Gabrilovich
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jun 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael I KoukourakisAdrian L Harris
Jul 15, 2011·Nature·Andrea FacciabeneGeorge Coukos
Aug 17, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Inna SerganovaJason A Koutcher
Sep 19, 2012·Proceedings of the National Academy of Sciences of the United States of America·Eric T ClambeyHolger K Eltzschig
Oct 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·Yuhui HuangMark C Poznansky
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dennie T FrederickJennifer A Wargo
Apr 5, 2013·The New England Journal of Medicine·Antoni RibasJedd Wolchok
Jun 19, 2013·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Amanda EustaceCatharine M L West
Jul 3, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Zaheed HusainVikas P Sukhatme
Jul 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Asif RizwanJason A Koutcher
Oct 1, 2013·Nature Immunology·Andrew L DoedensAnanda W Goldrath
May 20, 2014·Cancer Immunology Research·F Stephen HodiDavid McDermott
May 13, 2015·Seminars in Oncology·Sara LabianoIgnacio Melero
Dec 15, 2015·Gut·Floris ImhannAlexandra Zhernakova
Jan 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander MartensBenjamin Weide
Jun 9, 2016·Oncogene·B I RatnikovZ A Ronai

❮ Previous
Next ❯

Citations

Sep 29, 2020·Expert Opinion on Biological Therapy·Victor I Seledtsov, Alexei von Delwig
Aug 11, 2020·Cancer Cell International·Xixia ZhangZhiwei Cao
Jan 9, 2021·Neoplasia : an International Journal for Oncology Research·Fabrizio Marcucci, Cristiano Rumio
Feb 25, 2021·Melanoma Research·Roger Olofsson BaggeAlexander C J van Akkooi
Mar 30, 2021·Frontiers in Oncology·Jialing WuYimin Liu
May 1, 2021·International Journal of Molecular Sciences·Fabio ValentiAntonino Guerrisi
May 1, 2021·Cancers·Mattia GaruttiFabio Puglisi
May 27, 2021·Trends in Immunology·Dania Zhivaki, Jonathan C Kagan
Jul 3, 2021·Cancers·Pauline du Rusquec, Christophe Le Tourneau
Aug 17, 2021·Frontiers in Immunology·Indumathi ManoharanSanthakumar Manicassamy
Oct 5, 2021·Human Cell·Xingchen WangXiuzhen Han
Oct 14, 2021·Nature Reviews. Clinical Oncology·Filippo G Dall'OlioBenjamin Besse

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01791595
NCT01950390
NCT02603432
NCT02968303

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.